Eptinezumab-jjmr

(Vyepti®)

Vyepti®

Latest News

loading GIF

Drug updated on 5/17/2024

Dosage FormInjection (intravenous; 100 mg/mL)
Drug ClassCalcitonin gene-related peptide antagonists
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the preventive treatment of migraine in adults.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Eptinezumab-jjmr (Vyepti) is indicated for the preventive treatment of migraine in adults and has demonstrated a favorable safety profile across various studies, with no significant difference in treatment-related adverse events compared to placebo.
  • The review process involved 15 systematic reviews/meta-analyses that provided comprehensive information about Vyepti's comparison to other drugs regarding safety and effectiveness for preventing migraines in adults.
  • Compared to other monoclonal antibodies targeting the calcitonin gene-related peptide pathway and gepants, eptinezumab shows similar levels of safety. However, it has a slightly higher occurrence of infusion-site adverse events than placebos.
  • In terms of efficacy, eptinezumab consistently reduces monthly migraine days according to multiple systematic reviews and meta-analyses. It also stands out due to its rapid onset, which starts reducing migraine rates from day one after dosing.
  • When comparing eptinezumab's effectiveness against other CGRP-targeting therapies, results vary; some analyses suggest it is among the most effective treatments, while others favor different options.
  • Network meta-analyses highlight eptinezumab’s substantial effect on decreasing monthly headache days and achieving high responder rates, especially at its 300mg dosage level.
  • A study addressing cost-effectiveness found that although eptinezumab generated the most quality-adjusted life years (QALYs), topiramate was identified as more cost-effective by comparison within the UK context.
  • Subpopulation efficacy analysis reveals promising outcomes with the use of eptinezumab-jjmr, particularly at a 300mg dose, amongst patients who had a previous history of treatment failure.

Product Monograph / Prescribing Information

Document TitleYearSource
Vyepti (eptinezumab-jjmr) Prescribing Information.2022Lundbeck Seattle BioPharmaceuticals, Inc., Bothell, WA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Reporting quality and risk of bias analysis of published rcts assessing anti-cgrp monoclonal antibodies in migraine prophylaxis: a systematic review.2024Journal of Clinical Medicine
Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis.2023Cephalagia
Efficacy and safety of eptinezumab for migraine: a systematic review and meta-analysis.2023Journal of Research in Medical Sciences
Competing treatments for migraine: a headache for decision-makers.2023The Journal of Headache and Pain
Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: a systematic review and network meta-analysis of phase 3 randomised controlled trials.2023Cephalalgia
Comparison of indirect treatment methods in migraine prevention to address differences in mode of administration.2023Journal of Comparative Effectiveness Research
Clinical effectiveness of pharmacological interventions for managing chronic migraine in adults: a systematic review and network meta-analysis.2023The Journal of Headache and Pain
Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: a network meta-analysis.2022The Journal of Headache and Pain
Efficacy and safety of eptinezumab as preventive treatment for episodic/chronic migraine: a systematic review and meta-analysis.2022Clinical and Experimental Pharmacology and Physiology
Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for treatment of chronic migraine: a systematic review and network meta-analysis.2021Clinical Neurology and Neurosurgery
Different dosage regimens of eptinezumab for the treatment of migraine: a meta-analysis from randomized controlled trials.2021The Journal of Headache and Pain
Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine: a systematic review and network meta-analysis.2021Frontiers in Pharmacology
Efficacy of calcitonin gene-related peptide (CGRP) receptor blockers in reducing the number of monthly migraine headache days (MHDs): a network meta-analysis of randomized controlled trials.2021Journal of the Neurological Sciences
Comparative effectiveness and tolerability of the pharmacology of monoclonal antibodies targeting the calcitonin gene-related peptide and its receptor for the prevention of chronic migraine: a network meta-analysis of randomized controlled trials.2021Neurotherapeutics
Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials.2021The Journal of Headache and Pain

Clinical Practice Guidelines